Therapy Areas: Autoimmune
Annexon Biosciences' ANX005 granted US FDA fast track designation
25 September 2019 -

The US Food and Drug Administration (FDA) has granted fast track designation to US-based Annexon Biosciences' ANX005, intended to treat Guillain-Barre Syndrome (GBS), it was reported Tuesday.

ANX005 is a clinical-stage investigational monoclonal antibody for the treatment of patients suffering from autoimmune and neurodegenerative disorders. It is designed to block C1q and the complete classical complement pathway.

The company has reportedly completed a phase 1b clinical study of the product and aims to advance ANX005 into later-stage clinical trials in GBS disease. It is also planning to develop the product for additional autoimmune and neurodegenerative diseases.

Login
Username:

Password: